Forgot your account information?  |  Create a CME account

Company announces plans for two new canine cancer drugs

Published by Steve Coleman on May 01, 2012

Fido may benefit from a crossover drug developed to fight human cancer.

Bioniche Life Sciences Inc. has announced it plans to launch two products for canine cancer, one as early as July.

The product closest to market is a mammary tumor-fighter based on the company’s mycobacterial cell wall technology. It’s the same delivery system the company uses to deliver Phase II of its human bladder cancer treatment UrocidinTM.

"This is a major opportunity for the Company given that the global incidence of canine cancer is approximately 4.2 million new cases annually," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc. "It is the leading disease-related , cause of death in dogs, with approximately one in four dying of cancer."

Mammary tumors are the second only to skin cancer in dogs as a whole, but are the most-common tumors in female dogs and make up half of all cancer types.

The second product is an offshoot of animal testing used to determine whether or not Urocidin TM was safe for human use. Dogs tested showed few side effects when given large doses.

However, the drug did show promising results replenishing blood cells killed during chemotherapy. White blood cell counts were back to normal within 24-48 hours, the company says.

Bioniche says it’s currently conducting dose confirmation studies before starting the final licensing studies, which could take six months to complete. Plans call for the drug to first be brought to the North American market, then to Australia and Europe.

Found in: news

National Office

Alberta British Columbia
Manitoba New Brunswick
Newfoundland & Labrador Nova Scotia
Ontario Québec
Prince Edward Island Saskatchewan